Personalised Medicine

Diagnosing cancer: new process for identifying biomarkers established

7 April 2017 | By Niamh Marriott (Drug Target Review)

Scientists have established a process for identifying biomarkers for the diagnosis of different types of cancer.

£10 million pancreatic cancer research fund for precision medicine

24 March 2017 | By Niamh Marriott (Drug Target Review)

The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.

IDEA Bio-Medical Ltd.

New tool developed to help avoid adverse drug reactions

22 February 2017 | By Niamh Marriott (Drug Target Review)

Medicines are an important part of treating and preventing disease in adults and children.  The ideal medicine would have no side effects or adverse drug reactions (ADRs) as they are also called, but the reality is all medicines can cause unwanted effects, in some people.

AstraZeneca provide insight into biomarkers and personalised treatment at Asthma & COPD 2017

16 January 2017 | By SMi Group

SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...

Global partnership launched to enable personalised therapies in multiple sclerosis

5 January 2017 | By Niamh Marriott (Drug Target Review)

In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.

Exploring the need for mutation-specific treatments in cystic fibrosis

13 December 2016 | By Caroline Richards (Drug Target Review)

Despite that over 1,900 mutations of the cystic fibrosis transmembrane conductance regulator cause cystic fibrosis, only two treatment options exist.

Personalised Medicines In-Depth Focus 2016

11 December 2016 | By Caroline Richards (Drug Target Review), Dr Adrian Harel

In this Personalised Medicines In-Depth Focus, Dr Adrian Harel talks about the importance of developing a diagnostic test and better treatments for traumatic brain injury. Plus, Caroline Richards, Editor of Drug Target Review explores the need for mutation specific treatments in cystic fibrosis...

Versatile applications of next-generation sequencing in pharmaceutics

4 December 2016 | By Pushpanathan Muthuirulan (National Institutes of Health)

Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...

Anti-inflammatory drugs could treat symptoms of depression

18 October 2016 | By Niamh Louise Marriott, Digital Content Producer

Anti-inflammatory drugs, like those used to treat rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression...

CRISPR technology inactivates cancer mutations

1 September 2016 | By Niamh Louise Marriott, Digital Content Producer

CRISPR/Cas9 is likely one of the most revolutionary tools in biotechnology, with tremendous implications for a broad range of biological and medical disciplines. As programmable scissors this technology allows cleavage of DNA at predefined sites in the genome of cells...

MSD and Moderna to develop personalised cancer vaccines

29 June 2016 | By Victoria White, Digital Content Producer

Moderna and MSD will develop personalised cancer vaccines that utilise Moderna’s mRNA vaccine technology to encode a patient’s specific neoantigens...

Omics In-Depth Focus 2016

16 June 2016 | By Mona Elbadawi-Sidhu (NIH West Coast Metabolomics Center), Oliver Fiehn (NIH West Coast Metabolomics Center), Warwick Dunn (University of Birmingham)

Featured in this Omics In-depth Focus: The next revolution in stratified medicine-molecular phenotyping with metabolomics; Pharmacometabolomics as the key to personalised medicine...

Pharmacometabolomics as the key to personalised medicine

12 June 2016 | By Mona Elbadawi-Sidhu (NIH West Coast Metabolomics Center), Oliver Fiehn (NIH West Coast Metabolomics Center)

Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...

Children with cancer to be offered gene testing in personalised treatment initiative

31 March 2016 | By Victoria White

Children with cancer will be offered testing for genetic mutations in their tumours as part of an initiative to personalise children’s cancer treatment...